Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.

Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.

Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos

ASH 2020

American Society of Hematology (ASH) Annual Meeting and Exposition
05–08 December 2020

Lost of interesting data presented by Jennifer Woyach at #iwCLL2021 📊

🔸 High-risk features predict shorter response to BTKi
🔸 B2M and lymph node size may be helpful
🔸 BTKi resistance driven by specific mutations in many cases

@VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia

3

It's time for the relapsed/refractory CLL treatment session at #iwCLL2021!

We've just been watching Andrew Roberts' presentation on resistance to venetoclax 👀💻

Find iwCLL coverage here 👉http://ow.ly/mX2q50GbO4F👈

@VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia

3

Always great to catch up with @matteolambe at #ESMO21

Stay tuned to http://VJOncology.com for more updates!

@VJOncology @myESMO #ESMO21 #BCsm #BreastCancer

Chemo is not dead in CLL.
⁦@DrMDavids⁩ presents very intriguing data combining ibrutinib with CIT in young/fit CLL pts ⁦@iwCLL. A few ??: Could we do lower doses to mitigate tox?⁩does ibrut add anything for ighv mutated pts? Is the anti-cd20 really needed?
#iwcll2021

Looking beyond JAK inhibitors in MPN with @doctorpemm of @MDAndersonNews at the #TexasMPNWorkshop21👨‍⚕️

🎥 Watch here: http://ow.ly/VqmL50G9Avs

@UTHealthSA #MPNsm #TxMPNW21 #TexasMPNWorkshop21 #MyeloproliferativeNeoplasms #HemOnc #BloodCancerAwarenessMonth #BCAM

Load More...

ASH 2020

American Society of Hematology (ASH) Annual Meeting and Exposition
05–08 December 2020

Breaking Updates in Hematological-Oncology

The American Society of Hematology (ASH) 2020 Annual Meeting and Exposition was held on the 5–8 December.

Despite the pandemic, the virtual format showcased outstanding leaps in understanding and treatment in 2020, across malignancies.

Explore our coverage by disease type, including updates from key trials in which new agents are moving forwards.

View all videos

Lost of interesting data presented by Jennifer Woyach at #iwCLL2021 📊

🔸 High-risk features predict shorter response to BTKi
🔸 B2M and lymph node size may be helpful
🔸 BTKi resistance driven by specific mutations in many cases

@VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia

3

It's time for the relapsed/refractory CLL treatment session at #iwCLL2021!

We've just been watching Andrew Roberts' presentation on resistance to venetoclax 👀💻

Find iwCLL coverage here 👉http://ow.ly/mX2q50GbO4F👈

@VJHemOnc @iwCLL #CLLsm #LEUsm #Leukemia

3

Always great to catch up with @matteolambe at #ESMO21

Stay tuned to http://VJOncology.com for more updates!

@VJOncology @myESMO #ESMO21 #BCsm #BreastCancer

Chemo is not dead in CLL.
⁦@DrMDavids⁩ presents very intriguing data combining ibrutinib with CIT in young/fit CLL pts ⁦@iwCLL. A few ??: Could we do lower doses to mitigate tox?⁩does ibrut add anything for ighv mutated pts? Is the anti-cd20 really needed?
#iwcll2021

Looking beyond JAK inhibitors in MPN with @doctorpemm of @MDAndersonNews at the #TexasMPNWorkshop21👨‍⚕️

🎥 Watch here: http://ow.ly/VqmL50G9Avs

@UTHealthSA #MPNsm #TxMPNW21 #TexasMPNWorkshop21 #MyeloproliferativeNeoplasms #HemOnc #BloodCancerAwarenessMonth #BCAM

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter